- Home
- STCN vs CGTX Comparison
STCN vs CGTX Comparison
Compare STCN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- CGTX
- Stock Information
- Founded
- STCN 1986
- CGTX 2007
- Country
- STCN United States
- CGTX United States
- Employees
- STCN N/A
- CGTX N/A
- Industry
- STCN Advertising
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- STCN Consumer Discretionary
- CGTX Health Care
- Exchange
- STCN Nasdaq
- CGTX Nasdaq
- Market Cap
- STCN 63.4M
- CGTX 79.3M
- IPO Year
- STCN 1994
- CGTX 2021
- Fundamental
- Price
- STCN $10.40
- CGTX $0.54
- Analyst Decision
- STCN
- CGTX Buy
- Analyst Count
- STCN 0
- CGTX 6
- Target Price
- STCN N/A
- CGTX $8.00
- AVG Volume (30 Days)
- STCN 11.9K
- CGTX 588.8K
- Earning Date
- STCN 12-12-2024
- CGTX 11-08-2024
- Dividend Yield
- STCN N/A
- CGTX N/A
- EPS Growth
- STCN 203.29
- CGTX N/A
- EPS
- STCN 3.17
- CGTX N/A
- Revenue
- STCN $169,044,000.00
- CGTX N/A
- Revenue This Year
- STCN N/A
- CGTX N/A
- Revenue Next Year
- STCN N/A
- CGTX N/A
- P/E Ratio
- STCN $3.19
- CGTX N/A
- Revenue Growth
- STCN N/A
- CGTX N/A
- 52 Week Low
- STCN $7.36
- CGTX $0.34
- 52 Week High
- STCN $13.00
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- STCN 57.19
- CGTX 54.28
- Support Level
- STCN $9.90
- CGTX $0.50
- Resistance Level
- STCN $10.29
- CGTX $0.64
- Average True Range (ATR)
- STCN 0.39
- CGTX 0.07
- MACD
- STCN 0.11
- CGTX 0.02
- Stochastic Oscillator
- STCN 100.00
- CGTX 67.74
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.